Zobrazeno 1 - 10
of 116
pro vyhledávání: '"I. Mattavelli"'
Autor:
M Mapelli, T Capovilla, I Mattavelli, E Salvioni, A Marongiu, G Maranzano, C Paganin, C Vignati, P Palermo, G Sinagra, P Agostoni
Publikováno v:
European Heart Journal Supplements. 25:D121-D122
Background Practice guidelines recommend Sodium–glucose co–transporter–2 inhibitors (SGLT2–i) for patients with heart failure with reduced ejection fraction (HFrEF). Our study aimed to describe our population of patients with indications for
Autor:
M Mapelli, T Capovilla, A Marongiu, G Maranzano, E Salvioni, I Mattavelli, C Paganin, C Vignati, P Gugliandolo, V Mantegazza, A Garlaschè, G Sinagra, P Agostoni
Publikováno v:
European Heart Journal Supplements. 25:D122-D123
Background Sodium–glucose co–transporter–2 inhibitors (SGLT2–i) are currently a standard therapy for patients with heart failure with reduced ejection fraction (HFrEF). Still, their potential benefits on biomarkers, respiratory function param
Autor:
M Mapelli, I Mattavelli, E Salvioni, A Bonomi, P Palermo, C Banfi, S Paolillo, M Biondi, P Agostoni
Publikováno v:
European Heart Journal Supplements. 25:D162-D163
Background N–terminal pro–B–type natriuretic peptide (NT–proBNP) and soluble interleukin 1 receptor–like 1 ST2 (sST2) are biomarkers used to grade heart failure with reduced ejection fraction (HFrEF) severity. The first is associated with t
Autor:
M Mapelli, I Mattavelli, E Salvioni, S Paolillo, C Basile, F De Martino, C Vignati, D Magrì, V Mantegazza, G Tamborini, P Agostoni
Publikováno v:
European Heart Journal Supplements. 25:D228-D228
Background Sacubitril/Valsartan therapy has become a cornerstone of heart failure with reduced ejection fraction (HFrEF) pharmacological therapy due to its positive prognostic impact. However, conflicting results have emerged on the effects of sacubi
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M Mapelli, S Romani, D Magrì, M Merlo, M Cittar, M Masè, M Muratori, G Gallo, M Sclafani, C Carriere, D Zaffalon, E Salvioni, I Mattavelli, C Vignati, F De Martino, S Rovai, C Autore, G Sinagra, P Agostoni
Publikováno v:
European Heart Journal Supplements. 24
Aims Reduced cardiac output (CO) has been considered crucial in symptoms’ genesis in hypertrophic cardiomyopathy (HCM). We evaluated the cardiopulmonary exercise testing (CPET) response in HCM focusing on parameters strongly associated with stroke
Autor:
M Mapelli, E Salvioni, M Paneroni, P Gugliandolo, A Bonomi, S Scalvini, R Raimondo, S Sciomer, I Mattavelli, M La Rovere, P Agostoni
Publikováno v:
European Heart Journal Supplements. 24
Aims Cardiopulmonary exercise test (CPET) and six–minute walking test (6MWT) are frequently used in heart failure (HF). CPET is a maximal exercise, whereas 6MWT is a self–selected constant load test usually considered a submaximal, and therefore
Autor:
S Elisabetta, M Mapelli, A Bonomi, I Mattavelli, F De Martino, C Vignati, P Gugliandolo, P Agostoni
Publikováno v:
European Heart Journal Supplements. 24
Background The anaerobic threshold (AT), identifies the moment during a maximal exercise when hyperventilation occurs in response to the introduction of an anaerobic metabolism. Its value is indicative of the subject‘s training and/or health, it ca
Autor:
Giuseppe Vitale, Filippo M. Sarullo, Piergiuseppe Agostoni, Federica Re, Pietro Palermo, Massimo Mapelli, Fabrizio Veglia, Elisabetta Salvioni, Alice Bonomi, I. Mattavelli
Publikováno v:
European Journal of Preventive Cardiology
The high morbidity and poor survival rates associated with chronic heart failure still represent a big challenge, despite improvements in treatments and the development of new therapeutic opportunities. The prediction of outcome in heart failure is g
Autor:
Elisabetta Salvioni, Sara Rovai, Carlo Vignati, Alessandra Magini, I. Mattavelli, Fabiana De Martino, Paola Gugliandolo, Stefania Paolillo, Piergiuseppe Agostoni, Valentina Sassi, Alice Bonomi, Massimo Mapelli
Publikováno v:
Journal of Cardiovascular Medicine. 21:882-888
Aims Practice guidelines recommend sacubitril/valsartan for heart failure with reduced ejection fraction. The aim of our study was to describe the use of sacubitril/valsartan in real-world clinical practice to help identify patients best able to tole